NCT06597721

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 210 (estimated)
• Sponsor: Adcendo ApS · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the recommended dose and the safety and tolerability of ADCE-T02 when given as a single therapy over a range of different dose levels.

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	ADCE-T02	Administered intravenously

Timeline

• Start date: 2024-11-25
• Primary completion: 2026-06-30
• Completion: 2026-12-31
• First posted: 2024-09-19
• Last updated: 2026-04-17

Locations

11 sites across 2 countries: United States, Australia

Regulatory

• FDA-regulated drug study